The “Next Bitcoin”? 10 CENT Crypto Set to Explode

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Mikhail Eydelman net worth and biography

Mikhail Eydelman Biography and Net Worth

SVP of Vaxcyte

Mikhail is an accomplished legal executive who brings over 15 years of legal experience in multiple areas, including commercial agreements and partnerships, securities matters, business development, litigation, healthcare compliance and product launches. Most recently, Mikhail served as the General Counsel and Corporate Secretary at Sagent Pharmaceuticals, a commercial-stage pharmaceutical company, where he built the legal team and drove value across the organization. Previously, he was Assistant General Counsel for Integrated DNA Technologies, a supplier of nucleic acids acquired by Danaher Corporation, where he led the international legal function and supported the company’s strategic initiatives. Mikhail also held legal roles of increasing responsibility at Akorn, a publicly traded commercial-stage pharmaceutical company, where he supported overall business growth as the company quadrupled in size. Prior to that, he practiced law at the international law firms of Latham & Watkins, Allen & Overy and Bryan Cave. Mikhail earned his BA in Economics from Brandeis University and JD from New York University School of Law.

What is Mikhail Eydelman's net worth?: The estimated net worth of Mikhail Eydelman is at least $1.26 million as of February 1st, 2024. Mr. Eydelman owns 20,710 shares of Vaxcyte stock worth more than $1,257,511 as of April 28th. This net worth evaluation does not reflect any other investments that Mr. Eydelman may own. Learn More about Mikhail Eydelman's net worth.
How do I contact Mikhail Eydelman?: The corporate mailing address for Mr. Eydelman and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Mikhail Eydelman's contact information.
Has Mikhail Eydelman been buying or selling shares of Vaxcyte?: Mikhail Eydelman has not been actively trading shares of Vaxcyte in the last ninety days. Most recently, Mikhail Eydelman sold 1,667 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $73.87, for a transaction totalling $123,141.29. Following the completion of the sale, the senior vice president now directly owns 20,710 shares of the company's stock, valued at $1,529,847.70. Learn More on Mikhail Eydelman's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Mikhail Eydelman (SVP), Jeff Fairman (VP), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 33 times. They sold a total of 281,096 shares worth more than $16,832,337.62. The most recent insider tranaction occured on April, 23rd when CEO Grant Pickering sold 15,000 shares worth more than $928,800.00. Insiders at Vaxcyte own 3.6% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 4/23/2024.

Mikhail Eydelman Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2024	Sell	1,667	$73.87	$123,141.29	20,710
1/2/2024	Sell	1,667	$63.93	$106,571.31	20,710
12/7/2023	Sell	10,000	$56.50	$565,000.00	21,035
10/2/2023	Sell	20,000	$50.40	$1,008,000.00	20,487

Mikhail Eydelman Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $60.72

$59.41

$60.95

50 Day Range

MA: $67.96

$60.06

$81.05

2 Week Range

Now: $60.72

$41.57

$82.04

Volume

594,302 shs

Average Volume

690,375 shs

Market Capitalization

$6.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad